Epidemiology and aetiology of moderate to severe diarrhoea in hospitalised HIV-infected patients ≥5 years old in South Africa, 2018-2021: a case-control analysis

3 <u>Authors and affiliations</u>

4 Siobhan L. Johnstone^{1,2}, Linda Erasmus¹, Juno Thomas¹, Michelle J. Groome^{3,4}, Nicolette M. du

5 Plessis⁵, Theunis Avenant⁵, Maryke de Villiers⁶, Nicola A. Page^{1,7}

6 ¹Center for Enteric Diseases, National Institute for Communicable Diseases, a division of the National

7 Health Laboratory Service (NHLS), Johannesburg, South Africa; ²School of Public Health, Faculty of

8 Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ³Division of Public

9 Health Surveillance and Response, National Institute for Communicable Diseases, a division of the

10 National Health Laboratory Service (NHLS), Johannesburg, South Africa; ⁴ School of Pathology,

11 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;

12 ⁵Department of Paediatrics, Kalafong Provincial Tertiary Hospital, Faculty of Health Sciences,

13 University of Pretoria, Pretoria 0001, South Africa; ⁶ Department of Internal Medicine, Kalafong

14 Provincial Tertiary Hospital, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South

15 Africa; ⁷Department of Medical Virology, Faculty of Health Sciences, University of Pretoria, Private

16 Bag X323, Arcadia, 0007;.

Corresponding author: Siobhan L. Johnstone; <u>siobhanj@nicd.ac.za</u>; <u>siobhanjsa@gmail.com</u>; (+27)
73 332 7905

19 Short title: Aetiology of diarrhoea in hospitalised HIV-infected patients

20 Key words: Diarrhoea, diagnostics, aetiology, HIV, South Africa

21 Authors' contributions

22 S.L.J, N.A.P, M.J.G, L.E and J.T conceptualised and designed the study. S.L.J, N.A.P, N.D., T.A. and

23 M.dV completed and managed fieldwork and data collection. S.L.J, N.A.P, M.J.G, L.E and J.T acquired,

24 analysed and interpreted the data. S.L.J drafted the work. All authors reviewed the manuscript.

25 Abstract

Diarrhoea is a recognised complication of HIV-infection, yet there are limited local aetiological data
in this high-risk group. These data are important for informing public health interventions and
updating diagnostic and treatment guidelines. This study aimed to determine the pathogenic causes
for diarrhoeal admissions in HIV-infected patients compared to hospital controls between July 2018
and November 2021.

Admitted diarrhoeal cases (n=243) and non-diarrhoeal hospital controls (n=101) ≥5 years of age
were enrolled at Kalafong, Mapulaneng and Matikwana hospitals. Stool specimens/rectal swabs
were collected and pathogen screening performed on multiple platforms. Differences in pathogen
detections between cases and controls, stratified by HIV status, were investigated.

35 The majority (n=164, 67.5%) of diarrhoeal cases with known HIV status were HIV-infected.

36 Pathogens could be detected in 66.3% (n=228) of specimens, with significantly higher detection in

37 cases compared to controls (72.8% versus 50.5%, p<0.001). Amongst HIV-infected participants,

38 prevalence of *Cystoisospora* spp. was significantly higher in cases than controls (17.7% versus 0.0%,

39 *p*=0.028), while *Schistosoma* was detected more often in controls than cases (17.4% versus 2.4%,

40 *p*=0.009). Amongst the HIV-uninfected participants, prevalence of *Shigella* spp., *Salmonella* spp. and

41 Helicobacter pylori was significantly higher in cases compared to controls (36.7% versus 12.0%,

42 *p*=0.002; 11.4% versus 0.0%, *p*=0.012; 10.1% versus 0.0%, *p*=0.023).

43 Diarrhoeal aetiology differed by HIV status, with *Shigella* spp. (36.7%) and *Salmonella* spp. (11.4%)

44 having the highest prevalence amongst HIV-uninfected cases and Shigella spp. (18.3%),

45 *Cystoisospora* (17.7%), and *Cryptosporidium* spp. (15.9%) having the highest prevalence amongst

46 HIV-infected cases. These differences should be considered for the development of diagnostic and

47 treatment guidelines.

49 Introduction

50 Diarrhoeal diseases pose a significant health burden across the globe, causing over 1.6 million deaths 51 annually amongst all ages¹. The majority of these deaths occur in low- and middle-income countries 52 (LMICs), specifically in south Asia and Sub-Saharan Africa (SSA)¹. Despite a decrease in global 53 diarrhoeal mortality rates over the past two decades, decreases have not been uniform across age 54 groups or settings². Unsafe water, poor sanitation and hygiene (WaSH)¹, as well as malnutrition and 55 compromised immunity³ are the main risk factors associated with diarrhoeal morbidity and 56 mortality. Other risk factors identified in LMICs include residence in a slum, use of communal toilets 57 and exposure to animals⁴. Children under the age of 5 years are at the highest risk, however there is 58 a significant burden in older age groups, specifically in LMICs^{1,5}. Despite global improvements in 59 WaSH⁶, much of the remaining burden of diarrhoeal disease may be attributed to foodborne 60 pathogens⁷. Food safety is of specific concern in LMICs where there is increased consumption of 61 unsafe foods, use of effluent in agriculture and changes in food distribution networks with bulk 62 production and increased distance between production and consumption as well as large, often 63 poorly regulated, informal sectors⁷.

64 Studies from high-income countries (HICs) have shown the majority of diarrhoeal diseases in adults 65 seeking healthcare to be due to *Campylobacter* spp., *Salmonella* spp., norovirus and rotavirus^{8,9}. Aetiology differs in SSA, with a meta-analysis amongst all ages identifying the main causative 66 67 pathogens as Escherichia coli, Cryptosporidium, Cyclospora, Entamoeba and Shigella spp.¹⁰ There are 68 several reasons for these differences in aetiology including different exposures and risk factors 69 associated with poorer living conditions and poor underlying health. One important consideration is 70 the high prevalence of human immunodeficiency virus (HIV) in SSA¹¹. HIV is a known risk factor for 71 diarrhoea, with episodes in HIV-infected individuals more likely to be severe, prolonged and result in 72 hospitalisation with higher mortality rates than in HIV-uninfected individuals^{12,13}. The aetiology of 73 diarrhoea in HIV-infected individuals is known to shift with HIV disease progression and treatment¹⁴.

74 During early disease stages, while CD4+ counts are high and viral loads low, diarrhoea is often 75 related to HIV seroconversion. As disease progresses, diarrhoea is frequently caused by 76 opportunistic pathogens related to decreased immune function¹⁴. These pathogens include bacterial 77 infections, such as Mycobacteria, parasitic infections, such as Cystoisospora belli, Cyclospora, Strongyloides, Cryptosporidia, Microsporidia and viral infections, such as cytomegalovirus (CMV)^{14–16}. 78 79 Patients with low CD4+ cell counts are at increased risk for chronic diarrhoea⁴ and polyparasitic 80 infection¹⁷. The HIV infection itself may be responsible for a proportion of the pathogen-negative 81 cases, through HIV enteropathy and permanent damage to the gastrointestinal mucosa¹⁸, as well as changes in gut microbial populations leading to dysbiosis¹⁹. Mucosal damage reduces small bowel 82 villous surface area, causing diarrhoea through malabsorption²⁰ as well as defects to cellular and 83 84 humoral defence mechanisms in the gastrointestinal tract²¹. Pathogen-negative cases associated 85 with advanced HIV disease may also be related to gastrointestinal tract involvement by 86 Mycobacterium tuberculosis and/or avium²² which is difficult to diagnose. A Dutch study found that 87 34% of diarrhoeal cases in untreated HIV-infected individuals could not be explained by a known 88 causative agent, and hypothesized that these unexplained cases were due to the HIV-infection 89 itself²³. Initiation of antiretroviral treatment (ART), and accompanying increase in CD4+ cell count, is 90 associated with a shift in the aetiology of diarrhoea from opportunistic infectious causes to non-91 infectious causes²⁴. Data from both HICs and SSA show that although patients initiated on ART have 92 significantly reduced diarrhoeal incidence compared with those not on treatment, the overall diarrhoeal incidence remains high^{18,25}. A proportion of the remaining episodes in patients with well-93 94 controlled HIV may be drug-related¹⁸.

95 There are limited aetiological data on HIV-related diarrhoeal diseases in SSA, with the majority of 96 published studies focusing on children under the age of five years, with available data in older 97 children and adults being limited by diagnostic technology¹⁴. A review of laboratory records in 98 Botswana indicated that only 14% of stool specimens submitted for routine diagnostic testing for all 99 ages had a pathogen detected, of which 8% were bacteria and 6% parasites²⁶. *Shigella* spp. and

100 Salmonella spp. were the most commonly detected bacteria while Cystoisospora spp. and 101 *Cryptosporidium* spp. were the most commonly detected parasites. Viral testing was not done. 102 Although HIV status was not available for the participants in this analysis, Botswana is a high HIV 103 prevalence setting with an estimated 23.9% of the population between 15-49 years old being HIV-104 infected during the study time period²⁶. Contrary to these findings, a longitudinal cohort study of 105 Zambian adults with a 31% HIV seroprevalence (higher than the estimated population HIV 106 seroprevalence of 22%) found that pathogens could be detected in 99% of stool samples collected 107 (diarrhoeal and non-diarrhoeal patients combined), with Cryptosporidium spp., Cystoisospora spp. 108 and Citrobacter spp. being significantly more common in HIV-infected than HIV-uninfected 109 individuals⁵. They found that HIV-infected adults in the pre-ART era were 2.4 times as likely to suffer 110 from diarrhoea than HIV-uninfected adults and that this increased risk lasted throughout the infection rather than being limited to those with low CD4+ cell counts⁵. Meta-analysis data indicates 111 112 a high burden of *Cryptosporidium*, microsporidia and *Cystoisospora* in SSA specifically¹⁶. Another 113 recent meta-analysis identified South Africa as having the highest global Cryptosporidium prevalence 114 (57.0%, CI 95%: 24.4-84.5%), although they recognised that these estimates were based on limited 115 data²⁷. A study in rural South Africa found that 60% of patients suffering from chronic diarrhoea 116 were HIV-infected and that the majority of these infections were due to Campylobacter spp. (20%), 117 Plesiomonas shigelloides (17%), Aeromonas spp. (13%), Shigella spp. (10%), Salmonella spp. (10%) 118 and *E. coli* spp. (10%)²⁸. Testing did not include parasites or viruses and results were not stratified by 119 ART status. Other studies in African children have identified HIV-infection as a significant risk factor 120 for rotavirus infection^{13,29}. Very few studies in SSA in adults included screening for viruses, despite data from HICs showing that viruses (specifically norovirus and rotavirus) were responsible for as 121 122 much as 44% of diarrhoea in adults presenting to emergency departments⁹. Patients with advanced 123 HIV are at increased risk for diarrhoea due to CMV infection³⁰. As CMV is mainly diagnosed on endoscopic biopsy³¹, prevalence is likely underestimated. 124

125 South Africa currently has the highest HIV burden in the world, representing 19% of the global HIVinfected population³². It is estimated that 86% of HIV-infected adults in South Africa have been 126 127 diagnosed, with 57% of these on ART (50.8% - 72.7% by province)³³. Women, elderly patients, those 128 with inadequate access to WaSH facilities and those not yet initiated on ART, have the highest risk for developing diarrhoea amongst HIV-infected South Africans³⁴. The majority of data on HIV-related 129 130 diarrhoea comes from HICs with low HIV prevalence¹⁴. Since diarrhoeal aetiology is likely to vary between settings³⁵, there is a need for more targeted epidemiological studies¹⁸, specifically in LMICs 131 132 with high HIV prevalence. There are few studies in HIV-infected populations which investigate a 133 comprehensive range of pathogens or infections with multiple pathogens¹⁹. These data are 134 important for informing public health interventions and updating diagnostic and treatment 135 guidelines, especially since treatment is often based on guidelines rather than individual patient 136 diagnostics³⁶. This study aimed to determine the pathogenic causes for diarrhoeal admissions in HIV-137 infected patients compared to controls without diarrhoea at three South African hospitals between July 2018 and November 2021. 138

139

140 Methods

141 Case and control enrolment

Patients of all ages hospitalised with diarrhoea were enrolled at Kalafong, Mapulaneng and
Matikwana hospitals through the African Network for improved Diagnostics, Epidemiology and
Management of common Infectious Agents (ANDEMIA)³⁷. Kalafong Provincial Tertiary Hospital is
based on the western outskirts of Pretoria (Gauteng Province) and serves the generally low-income
communities residing in urban townships to the west of Pretoria³⁸. The rural sites included
Mapulaneng, a 180 bed district hospital, and Matikwana, a 250 bed regional hospital³⁹, both located
in Bushbuckridge district in Mpumalanga Province.

149 Cases were defined as patients admitted with diarrhoea (three or more loose or liquid stools over a 150 24 hour period) for any duration. Unmatched controls were defined as individuals presenting to the 151 hospital or clinic for reasons other than diarrhoea (vaccination clinic, orthopaedic or surgical wards), 152 without gastrointestinal symptoms (vomiting or diarrhoea) in the past 3 weeks. The study was 153 explained to patients fulfilling the study definition and an information leaflet provided. Written 154 informed consent was signed by patients \geq 18 years of age and by parents/guardians for patients <18 155 years. An assent form was signed for patients between 7-17 years. Surveillance Officers completed 156 investigation forms by interviewing the patient, parent/guardian and reviewing clinical notes and 157 laboratory results where available. HIV status was determined from the clinical notes and available 158 laboratory results. Stool specimens or rectal swabs were collected from both cases and controls. 159 Patients were enrolled within 48 hours of admission to exclude nosocomial infections. Cases were 160 enrolled from July 2018 to June 2021 and controls enrolled from October 2019 to November 2021. 161 Cases and controls unable to provide specimens and patients <5 years old were excluded from this 162 analysis.

163 Laboratory testing

Pathogen screening was performed on Fast-track Diagnostics (viral and bacterial gastroenteritis and stool parasite kits), Seegene Allplex (GI-Parasite and GI-Helminth(I) assays) as well as TaqMan Array Cards (TAC) (included pathogens indicated in Table S1). Monoplex PCR was used to determine final outcome where there were discrepant results between testing platforms for a specific target. Due to limited available TAC cards, cases with unknown HIV status were excluded from testing. Controls with unknown HIV status were included in the overall case-control analysis (since there were limited control specimens available) but were not included in the HIV specific case-control analysis.

171 Data management and statistical analysis

Results for CD4+ cell count were extracted from the National Health Laboratory Service (NHLS)
database for HIV-infected cases and were categorised into three classes (<200 cells/µl; 200-500

174 cells/ μ l; >500 cells/ μ l). Only CD4+ cell count results within 12 months of the enrolment were 175 included and where multiple results were available for a single patient, the results closest to the 176 time of enrolment were used. Demographic and socioeconomic characteristics for cases and controls 177 were compared. Clinical presentation for HIV-infected versus HIV-uninfected cases were compared. 178 Pathogen detection amongst case and control specimens were compared, stratified by HIV status. 179 Clinical presentation and pathogen detection for HIV-infected cases was compared between CD4+ 180 cell count categories and for ART and cotrimoxazole prophylaxis treatment. X²-test and Fisher's exact test were used for categorical variables and t-test for continuous variables. P-values<0.05 were 181 182 considered to be statistically significant. Stata software (version 14) was used for all analyses. 183 Ethical considerations 184 The ANDEMIA study was approved by the Human Research Ethics Committee (Medical) of the 185 University of the Witwatersrand (approval numbers M170403) and the University of Pretoria Faculty 186 of Health Sciences Research Ethics Committee (approval number 101/2017). The HIV sub-analysis was approved by the Human Research Ethics Committee (Medical) of the University of the 187 188 Witwatersrand (approval numbers M190663). 189 Results 190 Enrolment and patient characteristics 191 A total of 378 specimens for patients ≥5 years were collected during the study period, including 277 192 cases and 101 controls (Figure 1). Amongst cases, 164 (59.2%) were HIV-infected, 79 (28.5%) were 193 HIV-uninfected and 34 (12.3%) had unknown HIV status. Amongst controls, 23 (22.8%) were HIV-194 infected, 50 (49.5%) were HIV-uninfected and 28 (27.7%) had unknown HIV status. Cases with 195 unknown HIV status (n=34) were excluded (due to limited testing capacity), hence a total of 344 196 specimens were included in the analysis.

198 Figure 1: Specimens included in the analysis

199 The median age of included patients was 34 years (IQR of 23-47), with cases being slightly older 200 (median 36; IQR 26-51) than controls (median 31; IQR 17-38) (Table 1). The majority of patients were 201 female (59.4%) and from the rural sites (67.4%), with proportionally more controls coming from the 202 rural site than cases (82.2% versus 61.3%, p<0.001). Cases and controls were similar with respect to 203 household crowding and dietary habits. Both cases and controls had good access to electric or gas 204 cookers (86.1%), refrigerators (88.4%) and improved WaSH (94.8% access to improved water source 205 and 96.4% access to private latrines/flush toilets). CD4+ cell counts were available for 99 (60.4%) of 206 the 164 HIV-infected cases. Eight (8.1%) had counts >500 cells/µl, 21 (21.2%) were between 200-500 207 cells/µl and the majority (n=70, 70.7%) had <200 cells/µl. Information regarding ART was available 208 for 156 (95.1%) of the HIV-infected cases, of which 130 (83.3%) were on treatment. Mean CD4+ cells 209 counts were similar between those on ART (229.23 cells/µl) and those not on ART (169.7 cells/µl), 210 (p=0.418). Information regarding cotrimoxazole treatment was available for 151 HIV-infected 211 patients, of which 63 (41.7%) were on treatment.

	Total (n=344)	Cases (n=243)	Controls (n=101)	<i>p</i> -value
Age (years) –	34 (23-47)	36 (26-51)	31 (17-38)	<0.001 ^f
median (IQR)				
Male	129 (40.6%)	88 (36.2%)	41 (40.6%)	0.445
Rural	232 (67.4%)	149 (61.3%)	83 (82.2%)	<0.001
HIV-infected ^a	187/316 (59.2%)	164/243 (67.5%)	23/73 (31.5%)	<0.001
Education ^b				
None	13/337 (3.9%)	10/237 (4.2%)	3/100 (3.0%)	0.002 ^g
<= 6 years	53/337 (15.7%)	47/237 (19.8%)	6/100 (6.0%)	
7-10 years	107/337 (31.8%)	78/237 (32.9%)	29/100 (29.0%)	
>10 years	164/337 (48.7%)	102/237 (43.0%)	62/100 (62.0%)	
Household	2.0 (1.2)	2.0 (1.9)	2.0 (0.9)	0.733 ^f
crowding/people				
per room – mean				
(std. dev)				
Electric or gas	296 (86.1%)	210 (86.4%)	86 (85.1%)	0.757
cooker				
Refrigerator	289/327 (88.4%)	200/231 (86.6%)	89/96 (92.7%)	0.115

Improved water source ^c	326 (94.8%)	229 (94.2%)	97 (96.0%)	0.603 g
Treat drinking water ^d	45 (13.1%)	31 (12.8%)	14 (13.9%)	0.782
Toilet type				
Private flush	86/337 (25.5%)	62/241 (25.7%)	24/96 (25.0%)	0.604 ^g
Private latrine	239/337 (70.9%)	170/241 (70.5%)	69/96 (71.9%)	
Communal flush	8/337 (2.3%)	7/241 (2.9%)	1/96 (1.0%)	
Communal latrine	2/337 (0.6%)	1/241 (0.4%)	1/96 (1.0%)	
Other	2/337 (0.6%)	1/241 (0.4%)	1/96 (1.0%)	
Dairy ^e	156 (45.4%)	107 (44.0%)	49 (48.5%)	0.447
Deli meat ^e	103 (29.9%)	79 (32.5%)	24 (23.8%)	0.107
Eggs ^e	183 (53.2%)	127 (52.3%)	56 (55.5%)	0.590

^a For participants with known HIV status only; ^b highest level of education that the patient (or parent/caregiver

215 if patient is <15 years) has obtained; ^c piped water to an inside or outside tap (as opposed to river, rain or well

water or water from a truck); ^d by boiling or chemical treatment; ^e In the preceding 4 weeks; ^f t-test; ^g fisher's

217 exact test; denominators given when different to column headings due to missing data.

218 Clinical presentation of cases

219 HIV-infected cases were likely to experience symptoms for a longer duration before admission

220 (median of 5 days versus 2 days, *p*<0.001) and were more likely to have chronic or persistent

diarrhoea (8.5% versus 0.0%, p=0.006) than HIV-uninfected cases (Table 2). The most common

symptoms experienced by all cases were fatigue (182, 74.9%), weight loss (176, 72.4%), vomiting

223 (172, 70.8%), fever (168, 69.1%), abdominal pain (166, 68.3%) and nausea (165, 67.9%). HIV-infected

cases were more likely to suffer from weight loss (81.1% versus 54.4%, p<0.001) and nausea (72.0%

versus 59.5%, *p*=0.051), while HIV-uninfected cases were more likely to suffer from dysentery (15.2%

226 versus 4.3%, *p*=0.003).

227 <u>Table 2: Clinical presentation of diarrhoeal cases</u>

	Total (n=243)	HIV-infected (n=164)	HIV-uninfected (n=79)	<i>p</i> -value
Duration of symptoms before admission (days) – median (IQR)	4 (2-8)	5 (3-8)	2 (1-4)	<0.001 ^d
Chronic/persistent diarrhoea ^a	13 (5.4%)	13 (7.9%)	0 (0.0%)	0.011 ^e
Fatigue	182 (74.9%)	124 (75.6%)	58 (73.4%)	0.712
Weight loss	176 (72.4%)	133 (81.1%)	43 (54.4%)	<0.001
Vomiting	172 (70.8%)	118 (72.0%)	54 (68.4%)	0.564
Fever ^b	168 (69.1%)	113 (68.9%)	55 (69.6%)	0.910

Abdominal pain	166 (68.3%)	106 (64.6%)	60 (76.0%)	0.076	
Nausea	165 (67.9%)	118 (72.0%)	47 (59.5%)	0.051	
Respiratory	105 (43.2%)	77 (47.0%)	28 (35.4%)	0.090	
symptoms					
Headache	100 (41.2%)	68 (41.5%)	32 (40.5%)	0.887	
Chills	63 (25.9%)	48 (29.3%)	15 (19.0%)	0.087	
Arthralgia	51 (21.0%)	38 (23.2%)	13 (16.5%)	0.229	
Dermatological	31 (12.8%)	25 (15.2%)	6 (7.6%)	0.094	
symptoms					
Myalgia	24 (10.0%)	16 (9.8%)	8 (10.1%)	0.928	
Dysentery ^c	19 (7.8%)	7 (4.3%)	12 (15.2%)	0.003	
Neurological	10 (4.1%)	6 (3.7%)	4 (5.1%)	0.732 ^e	
symptoms					
Painful	4 (1.7%)	3 (1.9%)	1 (1.3%)	>0.99 ^e	
lymphadenopathy					

^a diarrhoea for 28 days or longer; ^b current temperature of >38°C or history of fever in the past 10 days; ^c

229 Dysentery defined as self-reported blood in the stool; ^d t-test; ^e fisher's exact test

230 Pathogen detection in specimens of cases and controls

231 Pathogens were detected in 66.3% (228) of specimens tested, with significantly higher detection in 232 cases compared with controls (72.8% versus 50.5%, p<0.001; Table 3). Bacteria were more prevalent 233 in cases compared with controls (50.2% versus 28.7%, p<0.001), specifically Shigella spp., Salmonella 234 spp. and *Helicobacter pylori* (24.3% versus 10.9%, *p*=0.005; 8.6% versus 1.0%, *p*=0.007 and 8.6% 235 versus 0.0%, p=0.001, respectively). Detection of viruses was significantly higher in cases compared 236 with controls (21.8% versus 10.9%, p=0.018), specifically for adenovirus (11.0% versus 4.0%, 237 p=0.038). Parasites were detected in 37.8% (130) of specimens tested, however, detection was not 238 significantly higher in cases than controls (40.7% versus 30.7%, p=0.080) with the available sample 239 size. Prevalence of Cystoisospora, Cryptosporidium spp. and Enterocytozoon spp. was significantly 240 higher in cases than controls (11.9% versus 0.0%, *p*<0.00; 11.1% versus 3.0%, *p*=0.012; 4.5% versus 241 0.0%, p=0.038, respectively). Blastocystis and Schistosoma were more prevalent amongst controls 242 than amongst cases (23.8% versus 10.3%, p=0.001; 6.9% versus 2.1%, p=0.025, respectively). Cases 243 were more likely than controls to have multiple pathogens detected (37.9% versus 22.8%, p=0.007). 244 Amongst HIV-infected participants, Cystoisospora spp. prevalence was significantly higher in cases 245 than in controls (17.7% versus 0.0%, p=0.028), while Schistosoma was detected more often in 246 controls compared with cases (17.4% versus 2.4%, p=0.009). Amongst the HIV-uninfected

247	participants, Shigella spp., Salmonella spp. and Helicobacter pylori were more prevalent amongst
248	cases than controls (36.7% versus 12.0%, <i>p</i> =0.002; 11.4% versus 0.0%, <i>p</i> =0.012; 10.1% versus 0.0%,
249	p=0.023). Norovirus GII, C. difficile, Campylobacter, Cystoisospora, Cryptosporidium spp. and
250	Enterocytozoon spp. were more prevalent amongst HIV-infected than HIV-uninfected participants
251	(6.4% versus 1.6%, <i>p</i> =0.032; 7.0% versus 0.8%, <i>p</i> = 0.010; 6.4% versus 0.8%, <i>p</i> = 0.018; 15.5% versus
252	0.01%, <i>p</i> <0.001; 15.0% versus 1.6%, <i>p</i> <0.001; 5.4% versus 0.8%, <i>p</i> =0.031). Shigella spp. and
253	Blastocystis were more prevalent amongst HIV-uninfected than HIV-infected participants (27.1%
254	versus 17.1%, p=0.032; 25.6% versus 8.0%, p<0.001). Shigella spp. (18.3%) and Cystoisospora (17.7%)
255	were the most prevalent pathogens detected in HIV-infected diarrhoeal cases, while Shigella spp.
256	(36.7%) and Salmonella spp. (11.4%) were the most prevalent pathogens in HIV-uninfected
257	diarrhoeal cases. Although Blastocystis was prevalent in HIV-uninfected cases, it was not associated
258	with diarrhoea as prevalence was significantly higher in HIV-uninfected controls (40.0% versus

259 16.5%, *p*<0.001).

	Overall – n	ª (%)			HIV-infect	ted – nª (%)			HIV-uninfected – nª (%)				<i>p</i> -
	Total (n=344)	Cases (n=243)	Controls (n=101)	<i>p</i> - value⁵	Total (n=187)	Cases (n=164)	Controls (n=23)	<i>p</i> - value⁵	Total (n=129)	Cases (n=79)	Controls (n=50)	<i>p</i> - value⁵	value ^c
Any pathogen	228 (66.3)	177 (72.8)	51 (50.5)	<0.001	138 (73.8)	124 (75.6)	14 (60.9)	0.132	84 (65.1)	53 (67.1)	31 (62.0)	0.555	0.097
Virus	64 (18.6)	53 (21.8)	11 (10.9)	0.018	43 (22.1)	40 (24.4)	3 (13.0)	0.296 ^e	20 (15.5)	13 (16.5)	7 (14.0)	0.707	0.101
Adenovirus	31 (9.0)	27 (11.1)	4 (4.0)	0.038 e	20 (10.7)	19 (11.6)	1 (4.4)	0.476 ^e	10 (7.8)	8 (10.1)	2 (4.0)	0.314 ^e	0.380
Adenovirus 40/41	3 (0.9)	3 (1.2)	0 (0.0)	0.558 ^e	2 (1.1)	2 (1.2)	0 (0.0)	>0.99 ^e	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 ^e	0.637 ^e
Norovirus	18 (5.2)	14 (5.8)	4 (4.0)	0.603 ^e	13 (7.0)	13 (7.9)	0 (0.0)	0.374 ^e	5 (3.9)	1 (1.3)	4 (8.0)	0.074 ^e	0.246
Norovirus GI	4 (1.2)	2 (0.8)	2 (2.0)	0.584 ^e	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 e	3 (2.3)	1 (1.3)	2 (4.0)	0.559 ^e	0.308 e
Norovirus GII	14 (4.1)	12 (4.9)	2 (2.0)	0.248 ^e	12 (6.4)	12 (7.3)	0 (0.0)	0.367 ^e	2 (1.6)	0 (0.0)	2 (4.0)	0.148 e	0.032 ^e
Enterovirus	16 (4.7)	12 (4.9)	4 (4.0)	0.787 ^e	12 (6.4)	10 (6.1)	2 (8.7)	0.645 ^e	4 (3.1)	2 (2.5)	2 (4.0)	0.641 ^e	0.296 ^e
CMV	3 (0.9)	3 (1.2)	0 (0.0)	0.558 ^e	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 ^e	0 (0.0)	0 (0.0)	0 (0.0)	-	0.273 ^e
Astrovirus	5 (1.5)	4 (1.7)	1 (1.0)	>0.99 ^e	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 ^e	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 ^e	>0.99 ^e
Rotavirus	2 (0.6)	2 (0.8)	0 (0.0)	>0.99 ^e	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 ^e	1 (0.8)	1 (1.3)	0 (0.0)	1.000 ^e	>0.99 ^e
Sapovirus	1 (0.3)	1 (0.4)	0 (0.0)	>0.99 ^e	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 ^e	0 (0.0)	0 (0.0)	0 (0.0)	-	>0.99 ^e
>1 virus detected	9 (2.6)	7 (2.9)	2 (2.0)	>0.99 ^e	7 (3.7)	7 (4.3)	0 (0.0)	0.600 ^e	2 (1.6)	0 (0.0)	2 (4.0)	0.148 ^e	0.318 ^e
Bacteria	151 (48.9)	122 (50.2)	29 (28.7)	<0.001	87 (46.5)	76 (46.3)	11 (47.8)	0.894	61 (47.3)	46 (58.2)	15 (30.0)	0.002	0.894
Shigella spp.	70 (20.4)	59 (24.3)	11 (10.9)	0.005	32 (17.1)	30 (18.3)	2 (8.7)	0.378 ^e	35 (27.1)	29 (36.7)	6 (12.0)	0.002	0.032
Salmonella spp.	22 (6.4)	21 (8.6)	1 (1.0)	0.007 ^e	13 (7.0)	12 (7.3)	1 (4.4)	>0.99 ^e	9 (7.0)	9 (11.4)	0 (0.0)	0.012 ^e	0.993
C. difficile	14 (4.1)	13 (5.4)	1 (1.0)	0.074 ^e	13 (7.0)	12 (7.3)	1 (4.4)	>0.99 ^e	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 ^e	0.010 e
Campylobacter	13 (3.8)	12 (4.9)	1 (1.0)	0.119 ^e	12 (6.4)	12 (7.3)	0 (0.0)	0.367 ^e	1 (0.8)	0 (0.0)	1 (2.0)	0.388 ^e	0.018 e
STEC	2 (0.6)	0 (0.0)	2 (2.0)	0.086 ^e	0 (0.0)	0 (0.0)	0 (0.0)	-	2 (1.6)	0 (0.0)	2 (4.0)	0.148 ^e	0.166 ^e
ETEC	11 (3.2)	9 (3.7)	2 (2.0)	0.519 ^e	7 (3.7)	5 (3.1)	2 (8.7)	0.207 ^e	4 (3.1)	4 (5.1)	0 (0.0)	0.157 ^e	>0.99 ^e
EPEC	21 (6.1)	14 (5.8)	7 (6.9)	0.631	15 (8.0)	11 (6.7)	4 (17.4)	0.094 ^e	6 (4.7)	3 (3.8)	3 (6.0)	0.676 ^e	0.237
EAEC	41 (11.9)	28 (11.5)	13 (12.9)	0.725	25 (13.4)	20 (12.2)	5 (21.7)	0.208	14 (10.9)	8 (10.1)	6 (12.0)	0.739	0.504
0157	4 (1.2)	4 (1.7)	0 (0.0)	0.325 ^e	3 (1.6)	3 (1.8)	0 (0.0)	>0.99 ^e	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 ^e	0.648 ^e
Plesiomonas	1 (0.3)	1 (0.4)	0 (0.0)	>0.99 ^e	1 (0.5)	1 (0.6)	0 (0.0)	>0.99 ^e	0 (0.0)	0 (0.0)	0 (0.0)	-	>0.99 ^e
Helicobacter pylori	21 (6.1)	21 (8.6)	0 (0.0)	0.001 ^e	13 (7.0)	13 (7.9)	0 (0.0)	0.374 ^e	8 (6.2)	8 (10.1)	0 (0.0)	0.023 ^e	>0.99

260 <u>Table 3: Pathogen detection in specimens of cases and controls, stratified by HIV-infection status</u>

>1 bacteria	45 (13.1)	37 (15.2)	8 (7.9)	0.067	23 (12.3)	20 (12.2)	3 (13.0)	>0.99 ^e	11 (8.5)	8 (10.1)	3 (6.0)	0.528 ^e	0.287
detected													
Parasite ^d	130 (37.8)	99 (40.7)	31 (30.7)	0.080	85 (45.5)	78 (47.6)	7 (30.4)	0.122	43 (33.3)	21 (26.6)	22 (44.0)	0.042	0.031
Cystoisospora	29 (8.4)	29 (11.9)	0 (0.0)	<0.001 e	29 (15.5)	20 (17.7)	0 (0.0)	0.028 ^e	0 (0.0)	0 (0.0)	0 (0.0)	-	<0.001 e
Cryptosporidium	30 (8.7)	27 (11.1)	3 (3.0)	0.012 ^e	28 (15.0)	26 (15.9)	2 (8.7)	0.537 ^e	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 ^e	<0.001
spp.													e
Blastocystis	49 (14.2)	25 (10.3)	24 (23.8)	0.001	15 (8.0)	12 (7.3)	3 (13.0)	0.403 ^e	33 (25.6)	13 (16.5)	20 (40.0)	0.003	<0.001
Giardia spp.	12 (3.5)	9 (3.7)	3 (3.0)	>0.99 ^e	7 (3.7)	7 (4.3)	0 (0.0)	0.600 ^e	4 (3.1)	2 (2.5)	2 (4.0)	0.641 ^e	>0.99 ^e
Enterocytozoon	11 (3.2)	11 (4.5)	0 (0.0)	0.038 ^e	10 (5.4)	10 (6.1)	0 (0.0)	0.614 ^e	1 (0.8)	1 (1.3)	0 (0.0)	>0.99 ^e	0.031 e
spp.													
Schistosoma	12 (3.5)	5 (2.1)	7 (6.9)	0.025	8 (4.3)	4 (2.4)	4 (17.4)	0.009 e	4 (3.1)	1 (1.3)	3 (6.0)	0.298 ^e	0.767 ^e
Dientamoeba	2 (0.6)	1 (0.4)	1 (1.0)	0.502 ^e	0 (0.0)	0 (0.0)	0 (0.0)	-	2 (1.6)	1 (1.3)	1 (2.0)	>0.99 ^e	0.166 ^e
>1 parasite	19 (5.5)	13 (5.4)	6 (5.9)	0.827	24 (12.8)	22 (13.4)	2 (8.7)	0.744 ^e	10 (7.8)	6 (7.6)	4 (8.0)	>0.99 °	0.152
detected													
Mixed infections	40 (11.6)	34 (14.0)	6 (5.9)	0.034		23 (14.0)	2 (8.7)	0.744 ^e	14 (10.9)	10 (12.7)	4 (8.0)	0.564 ^e	0.504
Virus-bacteria					25 (13.4)								
Virus-parasite	35 (10.2)	29 (11.9)	6 (5.9)	0.094	25 (13.4)	23 (14.0)	2 (8.7)	0.744 ^e	11 (8.5)	7 (8.9)	4 (8.0)	>0.99 °	0.183
Bacteria-parasite	72 (20.9)	60 (24.7)	12 (11.9)	0.008	46 (24.6)	41 (25.0)	5 (21.7)	0.734	23 (17.8)	16 (20.3)	7 (14.0)	0.366	0.152
>1 pathogen	115 (33.4)	92 (37.9)	23 (22.8)	0.007	73 (39.0)	66 (40.2)	7 (30.4)	0.366	40 (31.0)	26 (32.9)	14 (28.0)	0.557	0.143
detected													

^a Total is 344 for overall analysis and 316 for the HIV analysis due to 28 controls with unknown HIV-status being excluded from the HIV analysis; ^b *p*-value comparing

262 pathogen detection in cases versus controls (for HIV-infected and HIV-uninfected groups respectively); ^c*p*-value comparing pathogen detection in HIV-infected versus HIV-

263 uninfected persons (cases and controls combined); ^d The following parasites were screened for but not detected: *Vibrio cholerae*, *Yersinia enterocolitica*, *E. histolytica*,

264 Strongyloides spp., Cyclospora, Hymenolepsis, Ascaris, Taenia, Trichuris, Ancylostoma, Enterobius, Necator: ^e Fisher's exact test

265 Effect of CD4+ cell count and treatment on clinical presentation and pathogen detection amongst
 266 HIV-infected diarrhoeal cases

267 For HIV-infected cases, presentation did not differ by CD4+ cell count for duration of symptoms, 268 fever, vomiting, fatigue, nausea, respiratory symptoms, abdominal pain, dermatological symptoms, 269 chills, headache, dysentery, arthralgia, myalgia, neurological symptoms or painful lymphadenopathy 270 (Table S2). There was an increased proportion of cases reporting weight loss with lower CD4+ cell 271 counts (91.4%, 81.0% and 62.5% for CD4+ cell counts of <200, 200-500, >500 cells/mm³ respectively; 272 p=0.032). Pathogens were detected more frequently in cases with low CD4+ cell counts (75.7%, 273 42.9% and 37.5% for CD4+ cell counts of <200, 200-500, >500 cells/mm³ respectively; p=0.004) 274 (Table S3). Cryptosporidium spp. specifically, was detected more often in those with low CD4+ cell 275 counts (25.7%, 4.8% and 0.0% for CD4+ cell counts of <200, 200-500, >500 cells/mm³ respectively; 276 *p*=0.039).

277 Clinical presentation was similar amongst HIV-infected cases on ART and those not on ART (Table 278 S4). Those on cotrimoxazole prophylaxis were more likely to experience fatigue (88.9% versus 69.3%, 279 p=0.005), weight loss (90.5% versus 76.1%, p=0.023) and chills (50.8% versus 15.9%, p<0.001) then 280 those not on cotrimoxazole. Pathogen detection was similar amongst HIV-infected cases on ART and 281 those not on ART (72.3% versus 88.5%, p=0.082) (Table S5). Parasites, specifically Cystoisospora spp. were more commonly detected amongst patients on cotrimoxazole compared with those not on 282 283 cotrimoxazole (27.0% versus 11.4%, p=0.014). Other pathogens were found in similar proportions 284 across treatment groups.

285 Clostridioides difficile detection

C. difficile was detected in 14 cases, 13 of which were in HIV-infected patients (92.9%). Symptoms
were similar between cases in which *C. difficile* was detected and those without *C. difficile* detection,
however those with *C. difficile* detected were more likely to have had a longer duration of illness
before admission (6.5 (IQR 4-11) days versus 4 (IQR 2-7) days) (data not shown). It is important to

290 distinguish C. difficile colonisation from disease to avoid unnecessary antimicrobial therapy. The case 291 definition, as per the guidelines for diagnostic and clinical management of C. difficile from the South 292 African Society for Clinical Microbiology, includes onset of diarrhoea more than 48 hours after 293 admission, or diarrhoea that continues for 3 days post admission and where there is no likely 294 alternatively cause (no other pathogens detected or use of laxatives), or where the patient has had 295 an admission or antibiotics use in the past 12 weeks.⁴⁰ Three of the 14 cases did not match this case 296 definition as they did not have an admission in the past 12 weeks and had multiple pathogens 297 detected on PCR. These three cases were however HIV-infected. Five of the cases had no other 298 pathogens detected on PCR, all of which were HIV-infected. Eight of the cases did have a prior 299 admission, however the majority of these (n=6, 75.0%) had multiple pathogens detected on PCR. In 300 addition, the guidelines recommend that specimens testing positive for C. difficile on PCR (which is 301 highly sensitive for detection of C. difficile), should have further toxins A/B immunoassays performed 302 (which have high specificity for diagnosis of C. difficile infection). This was not done in the current 303 analysis.

304 Discussion

305 Despite advances in HIV treatment, diarrhoea amongst HIV-infected patients remains a significant 306 public health challenge¹⁹. Our study found that the majority (67.5%) of patients 5 years and older 307 with known HIV-status admitted to the study sites with diarrhoea were HIV-infected, highlighting the 308 importance of HIV-related illnesses among South African adults hospitalised with diarrhoea. The 309 Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 treatment target aims to ensure 310 that 90% of the HIV-infected population are diagnosed, 90% of those diagnosed are initiated on ART 311 and 90% of those on ART should achieve viral suppression⁴¹. A recent South African analysis 312 estimated that 70.7% of diagnosed HIV-infected individuals have initiated ART, and 87.4% of these 313 are thought to be virally suppressed⁴¹. Proportions reported in the current analysis reflect these 314 numbers, as 83.3% of HIV-infected patients with known ART status were on treatment, however a

315 large proportion of HIV-infected patients included in this analysis had CD4+ cell count <200 cells/µl 316 (70/99, 70.7%) indicating that they are unlikely to be virally suppressed. Mpumalanga (home 317 province to the majority of the patients included in this analysis) is the only South African province in 318 which the third-90 indicator value (the percentage of those on ART that are virally suppressed) is below 85%⁴¹. It is also likely that the study design was skewed towards detection of poorly 319 320 suppressed HIV cases as they are most likely to be hospitalised for diarrhoea. Diarrhoea in patients 321 with viral suppression will likely be seen at a clinic level. Further studies at clinic level are 322 recommended in order to include a broader spectrum of cases. The clinical presentation of 323 diarrhoea in HIV-infected cases differs to that of HIV-uninfected cases. HIV-infected diarrhoeal cases 324 were more likely to have symptoms for a longer duration before admission and to suffer from 325 weight loss and nausea. HIV-uninfected cases were more likely to suffer from dysentery. This finding 326 has not been reported in other studies, however it is likely related to aetiological differences 327 between HIV-infected and HIV-uninfected diarrhoeal patients. Amongst HIV-infected cases, patients 328 on cotrimoxazole were more likely to experience fatigue, weight loss and chills and were more likely 329 to have parasites detected, specifically *Cystoisospora* spp., compared to those not on cotrimoxazole. 330 This is an interesting finding since cotrimoxazole is the prescribed treatment for this pathogen. Since 331 all patients with CD4+ <200 cells/ μ l should receive cotrimoxazole prophylaxis, it can be used as a 332 surrogate marker for advanced HIV disease. However this finding may also point to changes in 333 Cystoisospora sensitivity for cotrimoxazole or may indicate that these patients are carriers or take 334 longer to clear the pathogen. The possibility of drug resistance should be further investigated in 335 future studies.

The use of molecular methods and the expanded panel of pathogens included in testing resulted in a high pathogen detection rate, with pathogen detection being significantly higher in cases compared with controls. Although viruses were commonly detected (18.5% of all specimens tested) and were more likely to be detected in cases as compared with controls, when stratified by HIV status, viruses were not significantly associated with diarrhoea in this study. Although this lack of association may

341 be partly due to asymptomatic carriage of viruses (specifically in HIV-uninfected patients), it is likely 342 that the sample size was insufficient to determine significant differences between cases and controls 343 when stratified by HIV status. Interestingly, norovirus GII was more prevalent in HIV-infected 344 individuals than HIV-uninfected individuals and detection in HIV-infected individuals was limited to 345 cases. Previous findings from South Africa have shown that HIV-infected children are more likely to 346 suffer poor outcomes related to norovirus infection⁴², however detection rates were similar amongst HIV-infected and –uninfected children. This increased detection of norovirus in HIV-infected patients 347 348 ≥5 years of age has not been previously described. Bacteria was detected in 43.9% of specimens 349 tested and was significantly associated with diarrhoea overall and amongst HIV-uninfected patients. 350 Interestingly, prevalence of bacterial pathogens was high in both cases and controls within the HIV-351 infected group. This was specifically due to the high prevalence of *E. coli* spp. (including ETEC, EPEC 352 and EAEC) amongst HIV-infected controls. High E. coli spp. colonisation rates in HIV-infected 353 patients have been documented in other settings⁴³. We found Shigella spp, Salmonella spp. and H. 354 pylori to be significantly associated with diarrhoea in the current study, specifically amongst HIV-355 uninfected patients. It's likely that the sample size was insufficient to detect a difference in 356 prevalence between cases and controls in the HIV-uninfected group. Campylobacter spp. and C. 357 difficile were detected more often in HIV-infected patients as compared with HIV-uninfected 358 patients but were not significantly associated with diarrhoea (likely due to small sample sizes). 359 As expected from literature¹⁴, parasite prevalence was significantly higher amongst HIV-infected 360 compared with HIV-uninfected patients, specifically Cystoisospora, Cryptosporidium spp. and 361 Enterocytozoon spp., although only Cystoisospora was significantly associated with diarrhoea 362 amongst HIV-infected patients. The case-control analysis indicated that Blastocystis and Schistosoma 363 are unlikely to be causative agents of diarrhoea since these pathogens were detected at higher rates 364 in controls than in cases. Prevalence of Schistosoma among healthy individuals has been reported to 365 be as high as 51.2% in the Democratic Republic of Congo and is likely to be higher in villages and 366 rural areas where water is collected from rivers and dam⁴⁴. Blastocystis has been noted as an

important cause of diarrhoea amongst immunosuppressed patients⁴⁵, however this was not found in
 the current study.

369 Diarrhoeal aetiology differed with HIV status, with Shigella spp. and Salmonella spp. being prevalent 370 amongst HIV-uninfected cases and Shigella spp., Cystoisospora, and Cryptosporidium spp. being 371 prevalent amongst HIV-infected cases. These differences should be considered during development 372 of diagnostic and treatment guidelines. This study highlights the importance of Shigella spp. in 373 diarrhoeal morbidity amongst adults (regardless of HIV status). According to the Global Burden of 374 Disease Study (GBD), Shigella spp. were the leading cause of diarrhoeal deaths amongst individuals 375 over the age of 5 years and the second leading cause of death in young children in 2016¹. While 376 there is currently no approved Shigella vaccine, there are several candidates which show promise for 377 efficacy testing⁴⁶. In order to introduce a candidate vaccine, burden estimates are required. 378 Although a larger sample size is required, this analysis gives an indication of the high burden of 379 Shigella spp. in our setting. Further work is required to determine if HIV-infected individuals should 380 be considered as a risk group for possible target should Shigella vaccine become available. 381 Our results are in line with clinical literature which indicates a shift in diarrhoeal aetiology with CD4+ 382 cell count amongst HIV-infected patients. Pathogen detection was high in those with CD4+ cell 383 counts <200 cells/µl, indicating increased opportunistic infections (specifically *Cryptosporidium* spp.). 384 Pathogens could only be detected in just over a third of cases with high CD4+ cell count (>500 385 cells/ μ l), suggesting that these cases are possibly drug-related. This finding may be useful for 386 treatment guidelines. It also highlights the importance of addressing diarrhoea in patients on ART 387 especially since chronic diarrhoea has been identified as an major cause of dropout from ART care 388 services⁴⁷.

Detection of *C. difficile* in this study was almost exclusive to HIV-infected participants (13/14, 92.9%;
 including 12 cases and 1 control). Data from another hospital study in Gauteng Province estimated
 that community acquired *C. difficile* infections represent only 1.3% of cases (with the remaining

392 98.7% being hospital acquired)⁴⁸. Our study design excluded cases of hospital-acquired diarrhoea, as 393 enrolment and specimen collection was done within 48 hours of admission. The 5.4% C. difficile 394 prevalence reported here is lower than systematic review estimates of 15.8% amongst symptomatic non-immunosuppressed in-patients from LMIC⁴⁹. This systematic review indicated similar rates 395 amongst immunosuppressed and non-immunosuppressed populations⁴⁹ whereas the current study 396 397 found that C. difficile was more commonly detected in HIV-infected cases than in -uninfected cases. 398 While not considered an opportunistic infection, C. difficile is associated with exposure to healthcare 399 settings and with the use of antibiotics, both of which are increased amongst HIV-patients⁵⁰. The increased management of HIV patients in an outpatient setting⁵¹ may dispute the inclusion of recent 400 401 admission as a criterion in the case definition. There is also growing evidence to suggest the 402 possibility of *C. difficile* being an important community-acquired pathogen⁵¹, and consideration of 403 this should be given in populations with high HIV prevalence.

404 A major limitation of this study was the small sample size which restricted the analysis (attributable 405 fractions and odds ratios could not be calculated as many categories had zero count). The ANDEMIA 406 study was not specifically aimed at enrolling HIV-infected cases and controls, therefore this analysis 407 relied on incidental HIV enrolments. Enrolment, specifically of controls, was also hampered by 408 COVID-19 restrictions. An extension of this analysis would benefit from enrolling controls from HIV 409 clinics. Viral load was not analysed here, since few recent results were available; thus recent CD4+ 410 cell count was used as a proxy. CD4+ cell counts were not available for all HIV-infected cases at the 411 time of admission. Many of those without CD4+ cell counts available were matched from NHLS data, 412 however these tests were not always performed at the same time as the enrolment. We used a cut 413 off of 12 months on either side of enrolment for CD4+ cell counts as this was deemed to be a 414 reasonable estimation of the CD4+ cell count at admission. In cases where there were significant 415 changes in CD4+ cell counts over time, these may have been incorrectly quantified. There were also limited data available for antibiotic use. Date of last dose was available, however start date for 416 417 antibiotic course was not collected. This has limitations specifically for the C. difficile analysis, since

418	we could not determine the length of antibiotic courses. Future studies should also investigate the
419	expansion of diagnostic testing for <i>M. avium</i> which was not done in the present study.
420	In conclusion, this study highlights the importance of HIV-related diarrhoea amongst South African
421	inpatients ≥5 years of age, and underscores the importance of research in a high HIV prevalence
422	setting in order to improve the understanding of aetiology of diarrhoea. These data are important
423	for development of guidelines and treatment protocols as well as for preventative interventions,
424	such as vaccine introduction. Our data specifically highlights the importance of Shigella spp. amongst
425	both HIV-infected and HIV-uninfected diarrhoeal patients. We suggest that research be expanded to
426	primary healthcare levels in order to include a broader spectrum of HIV disease, specifically to
427	investigate diarrhoea in individuals with well-controlled HIV.
428	Acknowledgments
429	We wish to acknowledge the ANDEMIA participants, funders, staff and clinical staff at the hospitals.
430	Thank you to Ann Christin Vietor for statistical assistance.
431	
432	
433	
434	
435	
436	
437	
438	

440 <u>References</u>:

- 1. Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SR, et al. Estimates of the global,
- 442 regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a
- 443 systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis.
- 444 2018;18(11):1211–28.
- Fischer Walker CL, Black RE. Diarrhoea morbidity and mortality in older children, adolescents,
 and adults. Epidemiol Infect. 2010;138:1215–26.
- Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, et al. Acute diarrhea in
 adults and children: A global perspective. J Clin Gastroenterol. 2013;47(1):12–20.
- 449 4. Dwivedi K, Prasad G, Saini S, Mahajan S, Lal S, Baveja U. Enteric opportunistic parasites
 450 among HIV infected individuals: associated risk factors and immune status. Jpn J Infect Dis.
 451 2007;60:76–81.
- Kelly P, Todd J, Sianongo S, Mwansa J, Sinsungwe H, Katubulushi M, et al. Susceptibility to
 intestinal infection and diarrhoea in Zambian adults in relation to HIV status and CD4 count.
 BMC Gastroenterol. 2009;9(7).
- 455 6. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H. A comparative risk
- 456 assessment of burden of disease and injury attributable to 67 risk factor clusters in 21
- regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
 Lancet. 2012;380(9859).
- 459 7. Grace D. Food safety in low and middle income countries. Int J Environ Res Public Heal.
 460 2015;12:10490–507.
- 461 8. Jansen A, Stark K, Kunkel J, Schreier E, Ignatius R, Liesenfeld O, et al. Aetiology of community462 acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. BMC Infect
 463 Dis. 2008;8(1):1–7.

- Bresee JS, Marcus R, Venezia RA, Keene WE, Morse D, Thanassi M, et al. The etiology of
 severe acute gastroenteritis among adults visiting emergency departments in the United
 States. J Infect Dis. 2012;205(9):1374–81.
- 467 10. Fletcher S, Stark D, Ellis J. Prevalence of gastrointestinal pathogens in Sub-Saharan Africa:
 468 systematic review and meta-analysis. J Public Heal Africa. 2011;2(2).
- 469 11. Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report [Internet]. 2014.
 470 Available from: https://unaids-
- 471 test.unaids.org/sites/default/files/unaids/contentassets/documents/unaidspublication/2014/
- 472 UNAIDS_Gap_report_en.pdf
- 473 12. Germani Y, Minssart P, Vohito M, Yassibanda S, Glaziou P, Hocquet D, et al. Etiologies of
- 474 acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in
- 475 relation to human immunodeficiency virus serostatus. Am J Trop Med Hyg. 2017;59(6):1008–
- 476

480

14.

14.

- 477 13. Acácio S, Nhampossa T, Quintó L, Vubil D, Sacoor C, Kotloff K, et al. The role of HIV infection
- 478 in the etiology and epidemiology of diarrheal disease among children aged 0–59 months in
- 479 Manhiça District, Rural Mozambique. Int J Infect Dis. 2018;73:10–7.
- 481 management of diarrhoea in the HIV-positive patient. Aliment Pharmacol Ther. 2011;34:587–
 482 603.

Feasey NA, Healey P, Gordon MA. Review article: the aetiology, investigation and

- Thomas P, Pollok R, Gazzard B. Enteric viral infections as a cause of diarrhoea in the acquired
 immunodeficiency syndrome. HIV Med. 1999;1:19–24.
- 485 16. Wang Z, Liu Q, Liu H, Li S, Zhang L, Zhao Y, et al. Prevalence of Cryptosporidium, microsporidia
 486 and Isospora infection in HIV-infected people: a global systematic review and meta-analysis.
 487 Parasites and Vectors. 2018;11(28).
 - 23

- Vyas N, Pathan N, Aziz A. Enteric pathogens in HIV-positive patients with diarrhoea and their
 correlation with CD4+ T-lymphocyte counts. Trop Parasitol. 2012;2(1):29–34.
- 490 18. Asmuth D, Clay P, Blick G, Chaturvedi P, MacFarlane K. Incidence and prevalence of diarrhoea
- 491 in HIV clinical trials in the recent post-cART era: analysis of data from 38 clinical trials from
- 492 2008-2017 over 21,000 patients. In: 22nd International AIDS Conference. Amsterdam; 2018.
- 493 19. Logan C, Beadsworth M, Beeching N. HIV and diarrhoea: what is new? Curr Opin Infect Dis.
 494 2016;29(5):486–94.
- 495 20. Harris E, Washington K. Manifestations of immunodeficiency in the GI tract. In: Odze R,
- 496 Goldblum J, editors. Surgical pathology of the GI tract, liver, biliary tract, and pancreas
- 497 (Second edition). 2nd ed. Elsevier Inc.; 2009. p. 81–96.
- Awole M, Gebre-Selassie G, Kassa T, Kibru G. Isolation of potential bacterial pathogens from
 the stool of HIV-infected and HIV-non-infected patients and their antimicrobial susceptibility
 patterns in Jimma Hospital, South West Ethiopia. Ethiop Med J. 2002;40:353–64.
- 501 22. Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human Immunodeficiency Virus-
- 502 Associated Diarrhea: Still an Issue in the Era of Antiretroviral Therapy. Dig Dis Sci.
- 503 2015;60(8):2236–45.
- S04 23. Oude Munnink B, Canuti M, Deijs M, de Vries M, Jebbink M, Rebers S, et al. Unexplained
 diarrhoea in HIV-1 infected individuals. BMC Infect Dis. 2014;14(22).
- 506 24. Call S, Heudebert G, Saag M, Wilcox C. The changing etiology of chronic diarrhea in HIV-
- 507 infected patients with CD4 cell counts less than 200 cells/mm3. Am J Gastroenterol.
- 508 2000;95(11):3142-6.
- 509 25. Rubaihayo J, Tumwesigye N, Konde-Lule J, Wamani H, Nakku-Joloba E, Makumbi F. Frequency
- 510 and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda.
- 511 BMC Res Notes. 2016;9(1).

512 26. Rowe J, Shah S, Motlhagodi S, Bafana M, Tawanana E, Truong H, et al. An epidemiologic
513 review of enteropathogens in Gaborone, Botswana: Shifting patterns of resistance in an HIV

514 epidemic region. PLoS One. 2010;5(6):e10924.

- 515 27. Ahmadpour E, Safarpour H, Xiao L, Zarean M, K H-N, Barac A, et al. Cryptosporidiosis in HIV-
- positive patients and related risk factors: A systematic review and meta-analysis. Parasite.
 2020;27(27).
- 518 28. Obi CL, Bessong PO. Diarrhoeagenic bacterial pathogens in HIV-positive patients with
 519 diarrhoea in rural communities of Limpopo Province, South Africa. J Heal Popul Nutr.
 520 2002;20(3):230–4.
- 521 29. Groome MJ, Madhi SA. Five-year cohort study on the burden of hospitalisation for acute
- diarrhoeal disease in African HIV-infected and HIV-uninfected children: Potential benefits of
 rotavirus vaccine. Vaccine. 2012;30(S1):A173–8.
- S24 30. Cheung T, Teich S. Cytomegalovirus infection in patients with HIV infection. Mt Sinai J Med.
 S25 1999;66(2):113–24.
- 526 31. Azer S, Limaiem G. Cytomegalovirus colitis. Florida: StatPearls; 2022. 6 p.
- 527 32. Legenza L, Barnett S, Rose W, Bianchini M, Safdar N, Coetzee R. Epidemiology and outcomes
- 528 of Clostridium difficile infection among hospitalised patients: results of a multicentre

retrospective study in South Africa. BMJ Glob Heal. 2018;3(4):e000889.

- Johnson L, Dorrington R, Moolla H. Progress towards the 2020 targets for HIV diagnosis and
 antiretroviral treatment in South Africa. South Afr J HIV Med. 2017;18(1):a694.
- 532 34. Moshabela M, Macpherson P, Ezard N, Frean E, Mashimbye L, Elliott J, et al. Clinical and
- 533 social determinants of diarrhoeal disease in a rural HIV/AIDS clinic , South Africa : a case-
- 534 control study. Int J STD AIDS. 2014;23(5):346–50.

535	35.	Elfstrand L, Floren C. Management of chronic diarrhea in HIV-infected patients: current
536		treatment options, challenges and future directions. HIV AIDS. 2010;2:219–24.
537	36.	Riddle MS, Dupont HL, Connor BA. ACG clinical guideline: Diagnosis, treatment, and
538		prevention of acute diarrheal infections in adults. Am J Gastroenterol. 2016;111(5):602–22.
539	37.	Schubert G, Achi V, Ahuka S, Belarbi E, Bourhaima O, Eckmanns T, et al. The African Network
540		for Improved Diagnostics, Epidemiology and Management of common infectious Agents.
541		BMC Infect Dis. 2021;21(1):539.
542	38.	Delport S, Swanepoel J, Odendaal P, Roux P. Incidence of retinopathy of prematurity in very-
543		low-birth-weight infants born at Kalafong Hospital, Pretoria. South African Med J.
544		2002;92(12):986–90.
545	39.	Msimang VMY, Page N, Groome MJ, Moyes J, Cortese MM, Seheri M, et al. Impact of
546		rotavirus vaccine on childhood diarrheal hospitalization after introduction into the South
547		African Public Immunization Program. Pediatr Infect Dis J. 2013;32(12):1359–64.
548	40.	Nana T, Moore C, Boyles T, Brink AJ, Cleghorn7 J, Devenish LM, et al. South African Society of
549		Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection
550		prevention and control guideline. South African J Infect Dis. 2020;35(1).
551	41.	Marinda E, Simbayi L, Zuma K, Zungu N, Moyo S, Kondlo L, et al. Towards achieving the 90–
552		90–90 HIV targets: Results from the South African 2017 national HIV survey. BMC Public
553		Health. 2020;20(1):1–12.
554	42.	Page NA, Groome MJ, Nadan S, Netshikweta R. Norovirus epidemiology in South African
555		children <5 years hospitalised for diarrhoeal illness between 2009 and 2013. Epidemiol Infect.
556		2017;
557	43.	Garcia C, Chincha O, Leon M, Iglesias D, Barletta F, Mercado E, et al. Short Report : High
558		Frequency of Diarrheagenic Escherichia coli in Human Immunodeficiency Virus (HIV) Patients

559		with and without Diarrhea in Lima , Perú. Am J Trop Med Hyg. 2010;82(6):1118–20.
560	44.	Madinga J, Id LM, Barbe B, Linsuke S, Hermy M, Heroes A, et al. Non-typhoidal Salmonella
561		intestinal carriage in a Schistosoma mansoni endemic community in a rural area of the
562		Democratic Republic of Congo. PLoS Negl Trop Dis. 2020;14(10):e0007875.
563	45.	Rao K, Sekar U, Iraivan KT, Abraham G, Soundararajan P. Blastocystis hominis — An Emerging
564		Cause of Diarrhoea in Renal Transplant Recipients. J Assoc Physicians India. 2003;51:719–21.
565	46.	Hosangadi D, Smith PG, Giersing BK. Considerations for using ETEC and Shigella disease
566		burden estimates to guide vaccine development strategy. Vaccine. 2019;37(50):7372–80.
567	47.	Asiimwe SB, Kanyesigye M, Bwana B, Okello S, Muyindike W. Predictors of dropout from care
568		among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment
569		clinic in sub-Saharan Africa. BMC Infect Dis. 2016;16(43).
570	48.	Godinho L, Feldman C. Clostridium difficile infection in Johannesburg, South Africa. Hosp
571		Pract. 2018;46(5):287–94.
572	49.	Forrester JD, Cai LZ, Mbanje C, Rinderknecht TN, Wren SM. Clostridium difficile infection in
573		low- and middle-human development index countries: a systematic review. Trop Med Int
574		Heal. 2017;22(10):1223–32.
575	50.	Revolinski SL, Munoz-Price LS. Clostridium difficile in Immunocompromised Hosts: A Review
576		of Epidemiology, Risk Factors, Treatment, and Prevention. Clin Infect Dis. 2019;68(12):2144–
577		53.
578	51.	Collini PJ, Kuijper E, Dockrell DH. Clostridium Difficile Infection in Patients with HIV/AIDS. Curr
579		HIV/AIDS Rep. 2013;10:273–82.
580		

582 <u>Supplementary tables:</u>

583 <u>Table S1: Pathogens included in molecular testing</u>

Pathogen	Testing platform
Viruses	
Norovirus GI	FTD viral gastroenteritis, TaqMan Array Cards
Norovirus GII	FTD viral gastroenteritis, TaqMan Array Cards
Human astrovirus	FTD viral gastroenteritis, TaqMan Array Cards
Rotavirus	FTD viral gastroenteritis, TaqMan Array Cards
Human adenovirus	FTD viral gastroenteritis, TaqMan Array Cards
Sapovirus	FTD viral gastroenteritis, TaqMan Array Cards
Enterovirus	TaqMan Array Cards
CMV	Monoplex PCR
Bacteria	
Campylobacer coli/jejuni/lari	FTD bacterial gastroenteritis, TaqMan Array Cards
Clostridioides difficile	FTD bacterial gastroenteritis, TaqMan Array Cards
Escherichia coli verotoxin positives	FTD bacterial gastroenteritis
Salmonella spp.	FTD bacterial gastroenteritis, TaqMan Array Cards
Shigella spp.	FTD bacterial gastroenteritis, TaqMan Array Cards
Enteroinvasive Escherichia coli	FTD bacterial gastroenteritis, TaqMan Array
Yersinia enterocolitica	FTD bacterial gastroenteritis, TaqMan Array Cards
EAEC	TaqMan Array Cards
EPEC	TaqMan Array Cards
ETEC	TaqMan Array Cards
STEC/VTEC	FTD bacterial gastroenteritis; TaqMan Array Cards
E. coli O157	TaqMan Array Cards
Parasites	
Plesiomonas shigelloides	TaqMan Array Cards
Entamoeba histolytica	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex
Cryptosporidium spp.	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex
Giardia lamblia	FTD enteric parasites, TaqMan Array Cards, SeeGene Allplex
Vibrio cholerae	TaqMan Array Cards
Helicobacter pylori	TaqMan Array Cards
Schistosoma	TaqMan Array Cards
Enterocytozoon spp.	TaqMan Array Cards, SeeGene Allplex
Strongyloides stercoralis	TaqMan Array Cards, SeeGene Allplex
Cytoisospora belli	TaqMan Array Cards
Blastocystis hominis	SeeGene Allplex
Dientamoeba fragilis	SeeGene Allplex
Cyclospora cayentanensis	SeeGene Allplex
Hymenolepsis nana	SeeGene Allplex

Ascaris lumbricoides	SeeGene Allplex
Taenia spp.	SeeGene Allplex
Trichuris trichiura	SeeGene Allplex
Ancylostoma duodenale	SeeGene Allplex
Enterobius vermicularis	SeeGene Allplex
Necator americanus	SeeGene Allplex

585 Table S2: Clinical presentation for HIV-infected cases, stratified by CD4+ cell counts

	CD4+ cell count	<i>p</i> -value			
	<200 cells/µl	200-500 cells/µl	>500 cells/µl		
	(n=70)	(n=21)	(n=8)		
Duration of	6 (3-10)	7 (3.5-12)	5.5 (3-7)	0.822	
symptoms before					
admission – median					
(IQR)					
Chronic/persistent	6 (8.6%)	2 (9.5%)	1 (12.5%)	0.855	
diarrhoea					
Weight loss	64 (91.4%)	17 (81.0%)	5 (62.5%)	0.032	
Fatigue	58 (82.9%)	16 (76.2%)	5 (62.5%)	0.293	
Nausea	6 (75.0%)	15 (71.4%)	6 (75.0%)	>0.99	
Vomiting	48 (68.6%)	14 (66.7%)	6 (75.0%)	>0.99	
Fever (current or	46 (65.7%)	14 (66.7%)	5 (62.5%)	>0.99	
history)					
Abdominal pain	41 (58.6%)	14 (66.7%)	4 (50.0%)	0.667	
Respiratory	33 (47.1%)	12 (57.1%)	1 (12.5%)	0.097	
symptoms					
Chills	32 (45.7%)	7 (33.3%)	3 (37.5%)	0.634	
Headache	32 (45.7%)	7 (33.3%)	4 (50.0%)	0.635	
Dermatological	13 (18.6%)	3 (14.3%)	0 (0.0%)	0.494	
symptoms					
Arthralgia	11 (15.7%)	6 (28.6%)	0 (0.0%)	0.171	
Myalgia	11 (15.7%)	1 (4.8)%	0 (0.0%)	0.334	
Neurological	5 (7.1%)	0 (0.0%)	1 (12.5%)	0.347	
symptoms					
Dysentery ^b	2 (2.9%)	0 (0.0%)	0 (0.0%)	>0.99	
Painful swollen glands	2 (2.9%)	0 (0.0%)	0 (0.0%)	>0.99	

^a CD4+ count within 12 months of enrolment only known for 99 of the 164 HIV-infected patients included in

587 molecular testing; ^b Dysentery defined as self-reported blood in the stool.

	CD4+ count ^a - n (%)	<i>p</i> -value		
	>500 cells/µl (n=8)	<200 cells/µl		
		(n=21)	(n=70)	
Any pathogen	5 (62.5)	12 (57.1)	59 (84.3)	0.022
Virus	2 (25.0)	5 (23.8)	19 (27.1)	>0.99
Adenovirus	0 (0.0)	5 (23.8)	8 (11.4)	0.170
Adenovirus 40/41	0 (0.0)	1 (4.8)	0 (0.0)	0.293
Norovirus	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
Norovirus Gl	0 (0.0)	0 (0.0)	0 (0.0)	-
Norovirus GII	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
Enterovirus	2 (25.0)	0 (0.0)	7 (10.0)	0.068
CMV	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
Astrovirus	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
Rotavirus	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
Sapovirus	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
>1 virus detected	0 (0.0)	1 (4.8)	5 (7.1)	>0.99
Bacteria	4 (50.0)	8 (38.1)	35 (50.0)	0.638
Shigella spp.	1 (12.5)	1 (4.8)	12 (17.1)	0.389
Salmonella spp.	0 (0.0)	0 (0.0)	7 (10.0)	0.322
C. difficile	0 (0.0)	1 (4.8)	9 (12.9)	0.450
Campylobacter	0 (0.0)	0 (0.0)	4 (5.7)	0.695
STEC	0 (0.0)	0 (0.0)	0 (0.0)	-
ETEC	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
EPEC	0 (0.0)	0 (0.0)	6 (8.6)	0.464
EAEC	1 (12.5)	4 (19.1)	8 (11.4)	0.622
0157	0 (0.0)	0 (0.0)	2 (2.9)	>0.99
Plesiomonas	0 (0.0)	1 (4.8)	0 (0.0)	0.293
Helicobacter pylori	2 (25.0)	2 (9.5)	4 (5.7)	0.109
>1 bacteria detected	0 (0.0)	1 (4.8)	14 (20.0)	0.131
Parasite ^b	2 (25.0)	8 (38.1)	39 (55.7)	0.145
Cystoisospora	1 (12.5)	4 (19.1)	12 (17.1)	>0.99
Cryptosporidium		1 (4.8)	19 (27.1)	0.028
spp.				
Blastocystis	1 (12.5)	2 (9.5)	5 (7.1)	0.563
Giardia spp.	0 (0.0)	1 (4.8)	4 (5.7)	>0.99
Enterocytozoon spp.	0 (0.0)	1 (4.8)	6 (8.6)	>0.99
Schistosoma	0 (0.0)	0 (0.0)	1 (1.4)	>0.99
>1 parasite detected	0 (0.0)	1 (4.8)	8 (11.4)	0.611
Mixed infections	. ,	, ,		
Virus-bacteria	1 (12.5)	4 (19.1)	9 (12.9)	0.793
Virus-parasite	1 (12.5)	3 (14.3)	12 (17.1)	>0.99
Bacteria-parasite	2 (25.0)	5 (23.8)	21 (30.0)	0.032

⁵⁹⁶

^a CD4+ count within 12 months of enrolment only known for 99 of the 164 HIV-infected cases; ^b The following

597 parasites were screened for but not detected: *Vibrio cholerae, Yersinia enterocolitica, E. histolytica,*

598 Strongyloides spp., Cyclospora, Hymenolepsis, Ascaris, Taenia, Trichuris, Ancylostoma, Enterobius, Necator,

599 Dientamoeba.

600 <u>Table S4: Clinical presentation of HIV-infected cases, stratified by treatment</u>

	Antiretrov	iral treatmer	nt ª - n (%)	Cotrimoxazole prophylaxis ^a - n (%)		
	Yes	No (n=26)	<i>p</i> -value	Yes (n=63)	No (n=88)	<i>p</i> -value
	(n=130)					
Duration of symptoms	5 (3-8)	4.5 (2-10)	0.489	5 (3-9)	4 (3-8)	0.410
before admission –						
median (IQR)						
Chronic/persistent	10 (7.7)	3 (11.5)	0.456	6 (9.5)	7 (8.0)	0.774
diarrhoea						
Weight loss	108	19 (73.1)	0.231	57 (90.5)	67 (76.1)	0.023
	(83.1)					
Fatigue	98 (75.4)	19 (73.1)	0.804	56 (88.9)	61 (69.3)	0.005
Nausea	92 (70.8)	19 (73.1)	0.813	43 (68.3)	65 (73.9)	0.451
Fever (current or self-	89 (68.5)	20 (76.9)	0.391	43 (68.3)	61 (69.3)	0.889
reported history in the						
past 10 days)						
Vomiting	89 (68.5)	22 (84.6)	0.153	42 (66.7)	67 (76.1)	0.200
Abdominal pain	83 (63.9)	18 (69.2)	0.600	42 (66.7)	59 (67.1)	0.961
Respiratory symptoms	59 (45.4)	13 (50.0)	0.667	29 (46.0)	41 (46.6)	0.946
Headache	50 (38.5)	12 (46.2)	0.464	30 (47.6)	33 (37.5)	0.214
Chills	39 (30.0)	6 (23.1)	0.477	32 (50.8)	14 (15.9)	<0.001
Arthralgia	32 (24.6)	2 (7.7)	0.069	13 (20.6)	21 (23.9)	0.640
Dermatological	21 (16.2)	2 (11.5)	0.768	10 (15.9)	14 (15.9)	0.995
symptoms						
Myalgia	14 (10.8)	1 (3.9)	0.469	10 (15.9)	6 (6.8)	0.075
Dysentery ^b	6 (4.6)	1 (3.9)	>0.99	3 (4.8)	4 (4.6)	>0.99
Neurological	5 (3.9)	1 (3.9)	>0.99	4 (6.4)	2 (2.3)	0.236
symptoms						
Painful swollen glands	3 (2.3)	0 (0.0)	>0.99	2 (3.2)	1 (1.1)	0.571

601 ^a ART status known for 156 and cotrimoxazole use known for 151 of 164 HIV-infected cases; ^b Dysentery

602 defined as self-reported blood in the stool.

	Antiretroviral treatment a - n (%)			Cotrimoxazole prophylaxis ^a - n (%)		
	No (n=26)	Yes (n=130)	<i>p</i> -value	No (n=88)	Yes (n=63)	<i>p</i> -value
Any pathogen	23 (88.5)	94 (72.3)	0.082	66 (75.0)	49 (77.8)	0.693
Virus	6 (23.1)	32 (24.6)	0.868	20 (22.7)	16 (25.4)	0.704
Adenovirus	3 (11.5)	14 (10.8)	>0.99	9 (10.2)	8 (12.7)	0.795
Adenovirus	0 (0.0)	1 (0.8)	>0.99			
40/41				1(1.1)	0 (0.0)	>0.99
Norovirus	3 (11.5)	10 (7.7)	0.456	6 (6.8)	7 (11.1)	0.354
Norovirus GI	0 (0.0)	1 (0.8)	>0.99	1 (1.1)	0 (0.0)	>0.99
Norovirus GII	3 (11.5)	9 (6.9)	0.423	5 (5.7)	7 (11.1)	0.240
Enterovirus	1 (3.9)	8 (6.2)	>0.99	4 (4.6)	4 (6.4)	0.720
CMV	0 (0.0)	3 (2.3)	>0.99	2 (2.3)	1 (1.6)	>0.99
Astrovirus	0 (0.0)	3 (2.3)	>0.99	0 (0.0)	2 (3.2)	0.172
Rotavirus	0 (0.0)	1 (0.8)	>0.99	0 (0.0)	1 (1.6)	0.417
Sapovirus	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	-
>1 virus	1 (3.9)	5 (3.9)	>0.99	1 (1.1)	5 (7.9)	0.083
detected						
Bacteria	16 (61.5)	62 (47.7)	0.197	44 (50.0)	32 (50.8)	0.923
Shigella spp.	5 (19.2)	24 (18.5)	>0.99	18 (20.5)	9 (14.3)	0.329
Salmonella spp.	2 (7.7)	10 (7.7)	>0.99	6 (6.8)	5 (7.9)	>0.99
C. difficile	2 (7.7)	10 (7.7)	>0.99	6 (6.8)	6 (9.5)	0.544
Campylobacter	1 (3.9)	10 (7.7)	0.692	4 (4.6)	7 (11.1)	0.202
STEC	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	-
ETEC	1 (3.9)	3 (2.3)	0.522	3 (3.4)	1 (1.6)	0.641
EPEC	2 (7.7)	8 (6.2)	0.673	6 (6.8)	5 (7.9)	>0.99
EAEC	2 (7.7)	18 (13.9)	0.531	10 (11.4)	8 (12.7)	0.803
0157	0 (0.0)	3 (2.3)	>0.99	1 (1.1)	2 (3.2)	0.571
Plesiomonas	0 (0.0)	1 (0.8)	>0.99	0 (0.0)	1 (1.6)	0.417
Helicobacter	4 (15.4)	8 (6.2)	0.117	6 (6.8)	6 (9.5)	0.544
pylori						
>1 bacteria	2 (7.7)	24 (18.5)	0.252	11 (12.5)	13 (20.6)	0.178
detected						
Parasite ^b	12 (46.2)	59 (45.4)	>0.99	33 (37.5)	37 (58.7)	0.010
Cystoisospora	4 (15.4)	24 (18.5)	>0.99	10 (11.4)	17 (26.9)	0.014
Cryptosporidium						
spp.	5 (19.2)	21 (16.2)	0.773	12 (13.6)	14 (22.2)	0.168
Blastocystis	4 (15.4)	6 (4.6)	0.063	8 (9.1)	2 (3.2)	0.195
Giardia spp.	1 (3.9)	5 (3.9)	>0.99	4 (4.6)	2 (3.2)	>0.99
Enterocytozoon						
spp.	0 (0.0)	10 (7.7)	0.215	4 (4.6)	6 (9.5)	0.321
Schistosoma	0 (0.0)	4 (3.1)	>0.99	3 (3.4)	1 (1.6)	0.641
>1 parasite						
detected	2 (7.7)	10 (7.7)	>0.99	7 (8.0)	5 (7.9)	>0.99
Mixed						
infections						
Virus-bacteria	3 (11.5)	20 (15.4)	0.768	11 (12.5)	11 (17.5)	0.394
Virus-parasite	2 (7.7)	19 (14.6)	0.531	8 (9.1)	11 (17.5)	0.126

614 <u>Table S5: Pathogen detection in specimens of HIV-infected cases, stratified by treatment</u>


Bacteria-	8 (30.8)	34 (26.2)	0.633	19 (21.6)	22 (34.9)	0.069
parasite						

615 ^a ART status known for 156 and cotrimoxazole use known for 151 of 164 HIV-infected cases; ^b The following

616 parasites were screened for but not detected: *E. histolytica, Strongyloides* spp., *Cyclospora, Hymenolepsis,*

617 Ascaris, Taenia, Trichuris, Ancylostoma, Enterobius, Necator, Dientamoeba.

618



^a Due to limited TAC tests available, cases with unknown HIV status were excluded from the analysis. Controls with unknown HIV status were included to increase sample size for the overall case-control analysis, but were not included in the HIV specific analysis.

Figure 1: Specimens included in the analysis

Figure 1